Inhibitors of p38 mitogen-activated protein kinase for the treatment of rheumatoid arthritis

Current Opinion in Investigational Drugs

Volumn 4, Issue 5, 2003, Pages 566-571

  Pargellis, Christopher ^a   Regan, John ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Inflammatory cytokines; MAPK; p38

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; 5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; 5 (4 PYRIDINYL) 4 (4 FLUOROPHENYL) 1 (4 PIPERIDINYL)IMIDAZOLE; AMG 548; ANTIINFLAMMATORY AGENT; COMPOUND 681323; CYTOKINE; DORAMAPIMOD; INFLIXIMAB; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; OKT 4; RO 320 1195; SB 242235; SB 281832; SCIO 323; SCIO 469; SYNAPTOPHYSIN; SYNAPTOPHYSIN INHIBITOR; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; VX 702;

ARTHRITIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL INFILTRATION; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME REGULATION; HUMAN; IC 50; LEUKOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; MONOCYTE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRANSLATION REGULATION;

ANIMALS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS, PHASE II; ENZYME INHIBITORS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES;

EID: 0038179379     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Dinarello CA: Inflammatory cytokines: Interleukin-1 and tumor necrosis factor as effector molecules in autoimmune diseases. Curr Opin Immunol (1991) 3(6):941-948.
2. Feldmann M, Brennan FM, Maini RN: Role of cytokines in rheumatoid arthritis. Annu Rev Immunol (1996) 14:397-440.
3. Koch AE, Kunkel SL, Strieter RM: Cytokines in rheumatoid arthritis. J Invest Med (1995) 43(1):28-38.
4. Rankin EC, Choy EH, Kassimos D, Kingsley GH, Sopwith AM, Isenberg DA, Panayi GS: The therapeutic effects of an engineered human anti-tumor necrosis factor α antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol (1995) 34(4):334-342.
5. Stack WA, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman J, Holmes G, Long R, Forbes A, Kamm MA: Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease. Lancet (1997) 349(9051):521-524.
6. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, Van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF et al: Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med (1999) 340(18):1398-1405.
7. Rutgeerts PJ: Review article: Efficacy of infliximab in Crohn's disease - Induction and maintenance of remission. Aliment Pharmacol Ther (1999) 13(Suppl 4):9-15.
8. Abbott Laboratories: Abbott Laboratories receives FDA approval earlier than anticipated for Humira (adalimumab) for the treatment of rheumatoid arthritis (RA). Press Release (2002) December 31.
9. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ: A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med (1999) 340(4):253-259.
10. Jarvis B, Faulds D: Etanercept: A review of its use in rheumatoid arthritis. Drugs (1999) 57(6):945-966.
11. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial. Lancet (2000) 356(9227):385-390.
12. Nuki G, Bresnihan B, Bear MB, McCabe D: Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2002) 46(11):2838-2846.
13. Nabozny GH, David CS: The immunogenetic basis of collagen induced arthritis in mice: An experimental model for the rational design of immunomodulatory treatments of rheumatoid arthritis. Adv Exp Med Biol (1994) 347:55-63.
14. Romas E, Gillespie MT, Martin TJ: Involvement of receptor activator of NFκB ligand and tumor necrosis factor-α in bone destruction in rheumatoid arthritis. Bone (2002) 30(2):340-346.
15. Shanahan JC, St. Clair W: Tumor necrosis factor-α blockade: A novel therapy for rheumatic disease. Clin Immunol (2002) 103(3 Pt 1):231-242.
16. Williams RO, Feldmann M, Maini RN: Cartilage destruction and bone erosion in arthritis: The role of tumour necrosis factor α. Ann Rheum Dis (2000) 59(Suppl 1):i75-i80. Summarizes the pivotal role of TNFα and the CD4+ T-cell in the progression of RA in both human disease and in the mouse CIA model.
17. Williams RO, Feldmann M, Maini RN: Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA (1992) 89(2):9784-9788.
18. Herlaar E, Brown Z: p38 MAPK signalling cascades in inflammatory disease. Mol Med Today (1999) 5(10):439-447.
19. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW, Strickler JE et al: A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature (1994) 372(6508):739-746. The first disclosure of p38 MAPK and its selective inhibition by a novel series of cytokine-suppessive anti-inflammatory drugs.
20. Wang XS, Diener K, Manthey CL, Wang S, Rosenzweig B, Bray J, Delaney J, Cole CN, Chan-Hui PY, Mantlo N, Lichenstein HS et al: Molecular cloning and characterization of a novel p38 mitogen-activated protein kinase. J Biol Chem (1997) 272(38):23668-23674.
21. Tibbles LA, Woodgett JR: The stress-activated protein kinase pathways. Cell Mol Life Sci (1999) 55(10):1230-1254.
22. Kyriakis JM, Avruch J: Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev (2001) 81(2):807-869. Extensive review of all MAPKs describing their activation as well as substrates and physiological effects.
23. Pietersma A, Tilly BC, Gaestel M, De Jong N, Lee JC, Koster JF, Sluiter W: p38 Mitogen activated protein kinase regulates endothelial VCAM-1 expression at the post-transcriptional level. Biochem Biophys Res Commun (1997) 230(1):44-48.
24. Yan W, Zhao K, Jiang Y, Huang Q, Wang J, Kan W, Wang S: Role of p38 MAPK in ICAM-1 expression of vascular endothelial cells induced by lipopolysaccharide. Shock (2002) 17(5):433-438.
25. Branger J, Van Den Blink B, Weijer S, Madwed J, Bos CL, Gupta A, Yong CL, Polmar SH, Olszyna DP, Hack CE, Van Deventer SJ et al: Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J Immunol (2002) 168(8):4070-4077.
26. Durie FH, Fava RA, Noelle RJ: Collagen-induced arthritis as a model of rheumatoid arthritis. Clin Immunol Immunopathol (1994) 73(1):11-18.
27. DeSilva DR, Jones EA, Feeser WS, Manos EJ, Scherle PA: The p38 mitogen-activated protein kinase pathway in activated and anergic Th1 cells. Cell Immunol (1997) 180(2):116-123.
28. Crawley JB, Rawlinson L, Lali FV, Page TH, Saklatvala J, Foxwell BM: T cell proliferation in response to interleukins 2 and 7 requires p38 MAP kinase activation. J Biol Chem (1997) 272(23):15023-15027.
29. Ward SG, Parry RV, Matthews J, O'Neill L: A p38 MAP kinase inhibitor SB203580 inhibits CD28-dependent T cell proliferation and IL-2 production. Biochem Soc Trans (1997) 25(2):304S.
30. Tamura K, Sudo T, Senftleben U, Dadak AM, Johnson R, Karin M: Requirement for p38α in erythropoietin expression: A role for stress kinases in erythropoiesis. Cell (2000) 102(2):221-231.
31. Wysk M, Yang DD, Lu HT, Flavell RA, Davis RJ: Requirement of mitogen-activated protein kinase kinase 3 (MKK3) for tumor necrosis factor-induced cytokine expression. Proc Natl Acad Sci USA (1999) 96(7):3763-3768.
32. Kotlyarov A, Neininger A, Schubert C, Eckert R, Birchmeier C, Volk HD, Gaestel M: MAPKAP kinase 2 is essential for LPS-induced TNF-α biosynthesis. Nat Cell Biol (1999) 1(2):94-97.
33. Lu HT, Yang DD, Wysk M, Gatti E, Mellman I, Davis RJ, Flavell RA: Defective IL-12 production in mitogen-activated protein (MAP) kinase kinase 3 (MKK3)-deficient mice. EMBO J (1999) 18(7):1845-1857.
34. Rincon M, Enslen H, Raingeaud J, Recht M, Zapton T, Su MS, Penix LA, Davis RJ, Flavell RA: Interferon-γ expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway. EMBO J (1998) 17(10):2817-2829.
35. Barton BE, James LC: The effect of dual inhibitor, SK&F 86002, on helper T cell functions. Immunopharmacol Immunotoxicol (1990) 12(1):105-121.
36. Brennan FM, Cope AP, Katsikis P, Gibbons DL, Maini RN, Feldman M: Selective immunosuppression of tumour necrosis factor-α in rheumatoid arthritis. Chem Immunol (1995) 60:48-60.
37. Newton RC, Decicco CP: Therapeutic potential and strategies for inhibiting tumor necrosis factor-α. J Med Chem (1999) 42(13):2295-2314.
38. Rodan GA, Martin TJ: Therapeutic approaches to bone diseases. Science (2000) 289(5484):1508-1514.
39. Matsumoto M, Sudo T, Saito T, Osada H, Tsujimoto M: Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-κB ligand (RANKL). J Biol Chem (2000) 275(40):31155-31161.
40. Lee JC, Kumar S, Griswold DE, Underwood DC, Votta BJ, Adams JL: Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology (2000) 47(2-3):185-201.
41. Brook M, Sully G, Clark AR, Saklatvala J: Regulation of tumour necrosis factor α mRNA stability by the mitogen-activated protein kinase p38 signalling cascade. FEBS Lett (2000) 483(1):57-61.
42. Tamura DY, Moore EE, Johnson JL, Zallen G, Aiboshi J, Silliman CC: p38 Mitogen-activated protein kinase inhibition attenuates intercellular adhesion molecule-1 up-regulation on human pulmonary microvascular endothelial cells. Surgery (1998) 124(2):403-407.
43. Baldassare JJ, Bi Y, Bellone CJ: The role of p38 mitogen-activated protein kinase in IL-1β transcription. J Immunol (1999) 162(9):5367-5373.
44. Caivano M, Gorgoni B, Cohen P, Poli V: The induction of cyclooxygenase-2 mRNA in macrophages is biphasic and requires both CCAAT enhancer-binding protein β (C/EBPβ) and C/EBP δ transcription factors. J Biol Chem (2001) 276(52):48693-48701.
45. Prichett W, Hand A, Sheilds J, Dunnington D: Mechanism of action of bicyclic imidazoles defines a translational regulatory pathway for tumor necrosis factor α. J Inflam (1995) 45(2):97-105. Describes the role of p38 MAPK in controlling cytokine expression by a novel translational control mechanism.
46. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G: Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: Implications for joint and gut-associated immunopathologies. Immunity (1999) 10(3):387-398.
47. Jackson PF, Bullington JL: Pyridinylimidazole based p38 MAP kinase inhibitors. Curr Top Med Chem (2002) 2(9):1011-1020. An overview of the pyridinylimidazole class of p38 inhibitors, including the historically significant SB-236080.
48. Cirillo PF, Pargellis C, Regan J: The non-diaryl heterocycle classes of p38 MAP kinase inhibitors. Curr Top Med Chem (2002) 2(9):1021-1035.
49. Pargellis C, Tong L, Churchill L, Cirillo PF, Gilmore T, Graham AG, Grob PM, Hickey ER, Moss N, Pav S, Regan J: Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol (2002) 9(4):268-272. This study combines structural and kinetic data describing BIRB-796, an allosteric inhibitor of p38 MAPK currently undergoing clinical trials for the treatment of RA.
50. Regan J, Breitfelder S, Cirillo P, Gilmore T, Graham AG, Hickey E, Klaus B, Madwed J, Moriak M, Moss N, Pargellis C et al: Pyrazole urea-based inhibitors of p38 MAP kinase: From lead compound to clinical candidate. J Med Chem (2002) 45(14):2994-3008.
51. Scios Inc: Scios announces progress with p38 MAP kinase program. Press Release (2003) January 06.
52. Haddad JJ: VX-745 (Vertex Pharmaceuticals). Curr Opin Invest Drugs (2001) 2(8):1070-1076.
53. Vertex Pharmaceuticals: Vertex moves to re-allocate resources from VX-745 in p38 MAP kinase program to accelerate development of second generation drug candidates VX-702 and VX-850. Press Release (2001) September 24.
54. Vertex Pharmaceuticas: Vertex pharmaceuticals provides corporate update: Company anticipates continued pipeline progress in 2003. Press Release (2003) January 6.
55. Wadsworth SA, Cavender DE, Beers SA, Lalan P, Schafer PH, Malloy EA, Wu W, Fahmy B, Olini GC, Davis JE, Pellegrino-Gensey JL et al: RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J Pharmacol Exp Ther (1999) 291(2):680-687.
56. Fijen JW, Zijlstra JG, De Boer P, Spanjersberg R, Cohen Tervaert JW, Van Der Werf TS, Ligtenberg JJ, Tulleken JE: Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers. Clin Exp Immunol (2001) 124(1):16-20.
57. Goldstein DM: The discovery and development of selective inhibitors of p38 MAP kinase from distinct chemical classes. Inflam Res (2002) 51(Suppl 2):Abs S19.
58. Adams JL, Boehm JC, Gallagher TF, Kassis S, Webb EF, Hall R, Sorenson M, Garigipati R, Griswold DE, Lee JC: Pyrimidinylimidazole inhibitors of p38: Cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity. Bioorg Med Chem Lett (2001) 11(21):2867-2870.
59. Wilson KP, McCaffrey PG, Hsiao K, Pazhanisamy S, Galullo V, Bemis GW, Fitzgibbon MJ, Caron PR, Murcko MA, Su MS: The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem Biol (1997) 4(6):423-431.
60. Boehm JC, Adams JL: New inhibitors of p38 kinase. Exp Opin Ther Pat (2000) 10(1):25-37.
61. Leo Pharmaceutical Products Ltd A/S: Drug development pipeline: P-1075, HEP-689, KH-1650, HL-10, CHS-828, Tinzaparin, GS-1590, EB-1089, EO-1428, HEP-688. Company Communication (2000) November 02.
62. GlaxoSmithKline plc: Drug development pipeline: SB-271046; BSYX-A110; thiolactomycin analogues; SB-238569; SB-236080; SB236049; GW-660511; SB-237376; SB-281832; SB-641257; SB-273005. Company Communication (2002) November 07.
63. GlaxoSmithKline plc: Product development pipeline - December 2002. Company Publication (2003) February 12.
64. Amgen Inc: Amgen provides business overview through 2005. Press Release (2003) February 25.